Literature DB >> 24707357

NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype.

Vijaya Galic1, Carrie J Shawber1, Claire Reeves1, Monjri Shah2, Aino Murtomaki1, Jason Wright1, Thomas Herzog1, Guo Xia Tong3, Jan Kitajewski1.   

Abstract

BACKGROUND: Notch family members function as both oncogenes and tumor suppressors. NOTCH2 is down-regulated in colon cancer, and reduced expression is associated with a less differentiated, more aggressive phenotype, and reduced overall survival. NOTCH2 has also been shown to have pro-apoptotic and growth suppressive effects in thyroid carcinoma, and carcinoid tumors. The expression pattern of NOTCH2 in ovarian cancer is unknown.
METHODS: An immunohistochemical analysis using a polyclonal antibody to the NOTCH2 intracellular domain was performed on a total of 119 ovarian carcinomas, and 7 serous borderline tumors, arranged onto tissue arrays. Normal ovarian and fallopian tube epithelium were used as controls. Specimens were scored as low or high NOTCH2 expression. The score distributions for the subtypes were analyzed with the chi square test.
RESULTS: Fifty two of 61 (85.2%) papillary serous, eight of 13 (61.5%) clear cell, and 23 of 30 (76.7%) endometrioid, demonstrated negative or lower NOTCH2 expression than normal fallopian tubal epithelium or ovarian surface epithelium. In contrast, 10 of 15 (66.7%) mucinous carcinomas had a high level of NOTCH2 expression and consistently demonstrated intense polarized staining (P<.001). The apical expression of NOTCH2 protein present in the normal fallopian tube epithelium and many borderline tumors was absent in the high grade carcinomas, most notably in papillary serous.
CONCLUSION: Decreased NOTCH2 expression is associated with the poorly differentiated serous epithelial ovarian carcinoma histology. Further studies are needed to assess the functional role of NOTCH2 in ovarian cancer and its effect on prognosis.

Entities:  

Keywords:  NOTCH2; immunohistochemistry; ovarian cancer; tumor suppressor

Year:  2013        PMID: 24707357      PMCID: PMC3975618          DOI: 10.7243/2052-7896-1-4

Source DB:  PubMed          Journal:  Pathol Discov        ISSN: 2052-7896


  26 in total

1.  Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

Authors:  Julia Willner; Kaitlyn Wurz; Kimberly H Allison; Vijaya Galic; Rochelle L Garcia; Barbara A Goff; Elizabeth M Swisher
Journal:  Hum Pathol       Date:  2007-01-29       Impact factor: 3.466

2.  Notch3 gene amplification in ovarian cancer.

Authors:  Joon T Park; Mei Li; Kentaro Nakayama; Tsui-Lien Mao; Ben Davidson; Zhen Zhang; Robert J Kurman; Charles G Eberhart; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.

Authors:  Irene Noguera-Troise; Christopher Daly; Nicholas J Papadopoulos; Sandra Coetzee; Pat Boland; Nicholas W Gale; Hsin Chieh Lin; George D Yancopoulos; Gavin Thurston
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

4.  Notch1 is involved in migration and invasion of human breast cancer cells.

Authors:  Jing Wang; Li Fu; Feng Gu; Yongjie Ma
Journal:  Oncol Rep       Date:  2011-07-22       Impact factor: 3.906

Review 5.  Mucinous tumors of the ovary: a review.

Authors:  William R Hart
Journal:  Int J Gynecol Pathol       Date:  2005-01       Impact factor: 2.762

6.  Formation and barrier function of tight junctions in human ovarian surface epithelium.

Authors:  Yihong Zhu; Julia Maric; Mikael Nilsson; Mats Brännström; P-O Janson; Karin Sundfeldt
Journal:  Biol Reprod       Date:  2004-02-18       Impact factor: 4.285

7.  NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations.

Authors:  Yi-Ping Fu; Hege Edvardsen; Alpana Kaushiva; Juan P Arhancet; Tiffany M Howe; Indu Kohaar; Patricia Porter-Gill; Anushi Shah; Hege Landmark-Høyvik; Sophie D Fosså; Stefan Ambs; Bjørn Naume; Anne-Lise Børresen-Dale; Vessela N Kristensen; Ludmila Prokunina-Olsson
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

8.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.

Authors:  M F Kohler; B J Kerns; P A Humphrey; J R Marks; R C Bast; A Berchuck
Journal:  Obstet Gynecol       Date:  1993-05       Impact factor: 7.661

9.  Notch2 expression is decreased in colorectal cancer and related to tumor differentiation status.

Authors:  Dake Chu; Jianyong Zheng; Weizhong Wang; Qingchuan Zhao; Yunming Li; Jipeng Li; Huahong Xie; Hongwei Zhang; Guanglong Dong; Chunsheng Xu; Mengbin Li; Dongli Chen; Gang Ji
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

10.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

View more
  7 in total

Review 1.  A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression.

Authors:  Hong-Li Li; Qian-Yu Li; Min-Jie Jin; Chao-Fan Lu; Zhao-Yang Mu; Wei-Yi Xu; Jian Song; Yan Zhang; Sai-Yang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553

2.  Lacrimal Gland Inflammation Deregulates Extracellular Matrix Remodeling and Alters Molecular Signature of Epithelial Stem/Progenitor Cells.

Authors:  Takeshi Umazume; William M Thomas; Sabrina Campbell; Hema Aluri; Suharika Thotakura; Driss Zoukhri; Helen P Makarenkova
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

3.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27

4.  Notch2 as a promising prognostic biomarker for oesophageal squamous cell carcinoma.

Authors:  Cong Wang; Qingbao Li; Fang Liu; Xuan Chen; Bowen Liu; Effat Un Nesa; Shanghui Guan; Lihui Han; Bingxu Tan; Nana Wang; Xintong Wang; Qingxu Song; Yibin Jia; Jianbo Wang; Ming Lu; Yufeng Cheng
Journal:  Sci Rep       Date:  2016-05-09       Impact factor: 4.379

5.  A powerful score-based statistical test for group difference in weighted biological networks.

Authors:  Jiadong Ji; Zhongshang Yuan; Xiaoshuai Zhang; Fuzhong Xue
Journal:  BMC Bioinformatics       Date:  2016-02-12       Impact factor: 3.169

6.  NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer.

Authors:  Dongyu Jia; Jesse Underwood; Qiuping Xu; Qian Xie
Journal:  Oncol Lett       Date:  2019-03-19       Impact factor: 2.967

7.  α-Mangostin-encapsulated PLGA nanoparticles inhibit colorectal cancer growth by inhibiting Notch pathway.

Authors:  Varun Chandra Boinpelly; Raj K Verma; Sudesh Srivastav; Rakesh K Srivastava; Sharmila Shankar
Journal:  J Cell Mol Med       Date:  2020-08-23       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.